Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypoxic intracellular macromolecules represent the collective cellular components, such as proteins, DNA, and RNA, that serve as the site of action for hypoxia-activated prodrugs (HAPs) and imaging tracers (Raleigh et al., 1998 [PMID: 9607521]). In tissues with low oxygen tension, these agents undergo enzymatic reduction by intracellular reductases to form highly reactive radical intermediates. In the presence of oxygen, these radicals are rapidly re-oxidized; however, in hypoxic conditions, they persist and form stable covalent adducts with cellular macromolecules or induce direct damage, such as DNA strand breaks (Wilson and Hay, 2011 [PMID: 21460873]). This mechanism is a cornerstone of tumor hypoxia imaging, where tracers like Fluoromisonidazole (FMISO) and Pimonidazole are "trapped" within hypoxic cells, and therapeutic strategies involving drugs like Tirapazamine or}
Bioreductive activation in low-oxygen environments leading to covalent binding or macromolecular damage
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxic intracellular macromolecules.